Apogee Therapeutics Inc (APGE) News
Track canonical SquawkNews coverage tagged to APGE, Apogee Therapeutics Inc. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 28 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Apogee board and executives resign at merger effective time
Apogee Therapeutics said board members and executive officers resigned effective at the merger’s Effective Time, and it entered parachute payment agreements with named executive officers on Sept. 1, 2026.
MNA | Sep 03, 2026, 01:04 PM UTC
L
Apogee Therapeutics to delist Nasdaq; trading suspended Sept. 4, 2026
Apogee Therapeutics notified Nasdaq it has consummated its merger and intends to remove all common stock from Nasdaq, requesting Nasdaq file Form 25 to delist and deregister. Trading will be suspended Sept. 4, 2026.
MNA | Sep 03, 2026, 01:04 PM UTC
L
AbbVie expects acquisition to cut 2027 adj EPS by about 46c
AbbVie expects the acquisition to negatively impact 2027 adjusted EPS by about 46c, with accretion beginning in 2032.
EARNINGS | Sep 03, 2026, 12:38 PM UTC
L
AbbVie expects acquisition to cut 2026 adj EPS by 14c (partial year)
AbbVie expects an acquisition to negatively impact 2026 adjusted EPS by 14c for a partial year.
EARNINGS | Sep 03, 2026, 12:38 PM UTC
M
Apogee Hldrs received $135.11 per share cash
Apogee Hldrs received $135.11 per share in cash, for total equity value of about $10.9 B.
EQUITY | Sep 03, 2026, 12:37 PM UTC
L
AbbVie Backs 3Q Adj EPS $3.84-Adj EPS $3.88 >ABBV
AbbVie Backs 3Q Adj EPS $3.84-Adj EPS $3.88 >ABBV
EARNINGS | Sep 03, 2026, 12:36 PM UTC
L
AbbVie backs FY26 adj EPS range $13.87-$14.07
AbbVie backs FY26 adjusted EPS of $13.87 to $14.07, per TradingView News.
EARNINGS | Sep 03, 2026, 12:36 PM UTC
M
AbbVie completes acquisition of Apogee Therapeutics
AbbVie completed its acquisition of Apogee Therapeutics.
MNA | Sep 03, 2026, 12:35 PM UTC
L
RNXT jumps to 52-week high amid biotech strength
RNXT shares rose to a 52-week high, +15%. Other biotech names cited: EOLS, CRNX, APGE.
EQUITY | Sep 01, 2026, 08:01 AM UTC
H
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
() -- Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday. As of July 6, the NYSE Arca Pharmaceutical Index
RATES | Jul 08, 2026, 03:11 PM UTC
M
Analysts Raise Targets
Top Wall Street analysts raise price targets for several stocks including Okta, International Seaways, and Ralliant
EQUITY | Jun 24, 2026, 01:00 PM UTC
H
AbbVie Acquires Apogee
AbbVie acquires Apogee Therapeutics in a $10.9 billion cash deal, expanding its immunology pipeline
EQUITY | Jun 23, 2026, 05:13 PM UTC
M
Citi Downgrades APGE
Citi downgrades APGE to Neutral, while other firms issue ratings on DRI, NKE, PRIM, ROST, SBRA, TLN, and ZION
EQUITY | Jun 23, 2026, 10:55 AM UTC
M
Healthcare Stocks Moving
Multiple healthcare stocks are moving in Monday's intraday session, with gainers including Tenon Medical and Aditxt, and losers including Aethlon Medical and Atlantic International
EQUITY | Jun 22, 2026, 05:23 PM UTC
H
DFTX +65% on Phase 3 Results
DFTX shares rise 65% on positive topline results from Phase 3 Emerge Study of DT120
EQUITY | Jun 22, 2026, 01:17 PM UTC
H
APGE +45% on Acquisition
AbbVie to acquire Apogee Therapeutics, sending APGE stock up 45% premarket
EQUITY | Jun 22, 2026, 12:21 PM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Monday's pre-market session, with gains and losses across the sector
EQUITY | Jun 22, 2026, 12:08 PM UTC
M
APGE: Trading Halt
APGE trading halted, quotation resumption pending
EQUITY | Jun 22, 2026, 11:15 AM UTC
H
ABBV Acquires APGE
AbbVie is acquiring Apogee for $135.11 per share in cash to expand its pipeline of clinical-stage candidates for inflammatory and immunological diseases
EQUITY | Jun 22, 2026, 11:05 AM UTC
H
ABBV Acquires APGE
AbbVie is acquiring Apogee Therapeutics to deepen its immunology portfolio
EQUITY | Jun 22, 2026, 11:03 AM UTC
M
GETY Leads Premarket Gainers
GETY and other stocks are leading premarket gainers, while AIXI and others are among the biggest losers
EQUITY | Jun 22, 2026, 10:58 AM UTC
H
SAGT Surges 76%
Sagtec Global shares rise 75.6% in pre-market trading after issuing financial year 2026 guidance projecting 35% revenue growth
EQUITY | Jun 22, 2026, 09:23 AM UTC
H
ABBV to Acquire APGE
AbbVie is closing in on a nearly $11 billion deal to acquire biotech company Apogee Therapeutics
EQUITY | Jun 22, 2026, 08:25 AM UTC
H
ABBV to Buy APGE
AbbVie is closing in on a nearly $11 billion deal to buy Apogee Therapeutics
EQUITY | Jun 19, 2026, 02:38 PM UTC